LMTX fails Phase III trial, monotherapy benefits seen
July 28, 2016Research and Development Alzheimer's, LMTX, TauRX, phase III, phase III failure
TauRX Therapeutics has reported Phase III clinical trial results for its novel tau aggregation inhibitor LMTX. The results indicated that …
Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin
July 28, 2016Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand
Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …
John Lechleiter to step down as Lilly CEO
July 27, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, John Lechleiter
Eli Lilly has announced that CEO John Lechleiter is set to retire, with David Ricks to assume the role as …
Shire and BMS secure NICE recommendations for oncology drugs
July 27, 2016Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …
Orkambi deemed not suitable for NHS use
July 27, 2016Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis
The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …
Pharma unit helps boost profits at Bayer
July 27, 2016Research and Development, Sales and Marketing Bayer, Q2, results
The pharmaceutical division at Bayer was the driving force, as the company announced a 5.7% increase in second quarter profit …
Eli Lilly Q2 2016 results surpass estimates
July 27, 2016Research and Development, Sales and Marketing Eli Lilly, financial report
Eli Lilly has released its financial report for the second quarter of 2016, noting a number of promising results. The …
Failure in pivotal Phase III study obliterates stock at Tokai Pharmaceuticals
July 27, 2016Research and Development phase III, prostate cancer, tokai pharmaceuticals
Shares at Tokai Pharmaceuticals have been sent into freefall following the suspension of a pivotal Phase III trial for their …
GSK announces significant post-Brexit UK investment
July 27, 2016Manufacturing and Production, Research and Development GSK, UK, brexit, investment
GlaxoSmithKline has given the UK life sciences industry a major boost in the post-Brexit landscape with an announcement that £275 …
Innovate UK appoints first director of Health and Life Sciences
July 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ian Campbell, Innovate UK, appointment, health and life sciences
Ian Campbell has been named by Innovate UK as its first director for Health and Life Sciences. Innovate UK is …
New drugs to utilise DNA damage response to kill cancer cells
July 26, 2016Research and Development, Sales and Marketing AstraZeneca, Cancer, Wellcome Trust, chemotherapy, dna damage response, university of sussex
The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …
Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial
July 26, 2016Research and Development Celgene, Revlimid, lymphoma
Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …
BMS names Fouad Namouni as new oncology development head
July 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo
Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …
Gilead lowers full-year guidance as sales and profits down in Q2
July 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing 2016, Gilead, Q2, results
Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …
IBS-D treatment Truberzi receives positive opinion from CHMP
July 26, 2016Manufacturing and Production, Sales and Marketing Allergan, EU, Truberzi, diarrhoea. CHMP, irritable bowel syndrome
Global pharmaceutical company Allergan has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of …
Darzalex receives breakthrough designation in multiple myeloma from FDA
July 26, 2016Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …
AbbVie and BMS partner for Rova-T, Opdivo, Yervoy cancer combo
July 26, 2016Manufacturing and Production, Research and Development AbbVie, BMS, Yervoy, opdivo, rova-t
AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …
CHMP issues positive opinion for Orencia Rheumatoid Arthritis treatment
July 25, 2016Manufacturing and Production, Sales and Marketing BMS, CHMP, Orencia, rheumatoid arthritis
Bristol-Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion of …
The ethical battle for the future of pharma
July 25, 2016Drug pricing, ethics in pharma
A battle is raging for the soul of the pharma industry and the stakes are high. Those companies seeking to …
MHRA approves Sanofi Pasteur MSD’s four-strain influenza vaccine for UK use
July 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing MHRA, Sanofi pasteur msd, UK, Vaccine, flu, influenza
Sanofi Pasteur MSD has announced the approval of the latest addition to its family of influenza vaccines in the UK: …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
